A Study of LBP-MARCO and Ruxolitinib in People With Graft-Versus-Host Disease (GVHD)

Full Title

Pilot Study of Live Biotherapeutic Product (LBP) MARCO (Microbiota Augmentation to Reestablish Commensal Organisms) Combined with Ruxolitinib for Patients with Steroid Refractory or Intolerant Gastrointestinal Acute Graft-versus-Host Disease (aGVHD) After Allogeneic Cell Transplantation (Allo-HCT) (MARCO-GVHD Trial)

Purpose

To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.

Contact

For more information or to see if you can join this study, please call Dr. Doris Ponce’s office at 646-608-3739.

Protocol
26-268
Phase
Phase I (phase 1)
Disease Status
Newly Diagnosed & Relapsed/Refractory
Investigator
Doris M. Ponce
Co-Investigators
Jonathan Peled
Diseases
Graft-Versus-Host Disease (GVHD)
Locations
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Commack Nonna’s Garden Foundation Center
Memorial Sloan Kettering Basking Ridge
Memorial Sloan Kettering Westchester
Memorial Sloan Kettering Monmouth
Memorial Sloan Kettering Bergen
Memorial Sloan Kettering Nassau
ClinicalTrials.gov ID
NCT07913672
ClinicalTrials.gov
Visit ClinicalTrials.gov for full clinical trial description